Ignite Creation Date:
2024-05-06 @ 12:02 AM
Last Modification Date:
2024-10-26 @ 10:43 AM
Study NCT ID:
NCT01476462
Status:
COMPLETED
Last Update Posted:
2012-05-24
First Post:
2011-07-13
Brief Title:
Second Malignant Neoplasms After Childhood ALL Therapy
Sponsor:
Rigshospitalet Denmark
Organization:
Rigshospitalet Denmark
Study Overview
Official Title:
Second Malignant Neoplasms After Childhood ALL Therapy An International Ponte di Legno Study
Status:
COMPLETED
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PdL-SMN1
Brief Summary:
Development of a second neoplasm SMN during or after therapy for childhood acute lymphoblastic leukemia ALL is a rare event generally associated with a poor prognosis In this international study we analyze subtypes of SMN in relation to their initial leukemia characteristics and treatment and their subsequent overall survival
Detailed Description:
To explore epidemiology potential risk factors and survival rates of second cancers occurring as the first event in childhood acute lymphoblastic leukemia the involved study groups will collect anonymous data on all such cases diagnosed within the last decades to form a common database with predefined variables comprising the clinical biological and cytogenetic characteristics myeloid neoplasias only as well as outcome Furthermore we will register the clinical biological and cytogenetic characteristics of the acute lymphoblastic leukemia as well as type of treatment given
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None